Urinary Tract Infection Treatment Market Report 2026

Urinary Tract Infection Treatment Market Overview

• Urinary Tract Infection Treatment market size has reached to $10.76 billion in 2025 • Expected to grow to $12.9 billion in 2030 at a compound annual growth rate (CAGR) of 3.8% • Growth Driver: Urinary Tract Infection Treatment Market Surges In Response To Escalating Prevalence • Market Trend: Next-Generation Oral Antibiotics Offer Hope Against Drug-Resistant Utis • North America was the largest region in 2025.

What Is Covered Under Urinary Tract Infection Treatment Market?

Urinary tract infection treatment refers to the medical procedures and methods used to remove the bacterial infection affecting the urinary system. Urinary tract infections can damage the bladder, urethra, ureters, kidneys, and other areas of the urinary system. The main types of drug class in urinary tract infection treatment are penicillin and combinations, quinolones, cephalosporin, aminoglycoside antibiotics, sulphonamides, azoles and amphotericin B, tetracycline and nitrofurantoin. Penicillin refers to a beta-lactamase antibacterial medication used to manage and treat a wide range of infections. In urinary tract infection treatment, penicillin is effective against the common bacteria that cause UTIs and is well tolerated. The various indications are complicated UTI and uncomplicated UTI. The distribution channels are hospital pharmacies, gynecology, and urology clinics, drug stores, retail pharmacies, and online drug stores.

What Is The Urinary Tract Infection Treatment Market Growth Forecast?

The urinary tract infection treatment market size is expected to see steady growth in the next few years. It will grow to $12.9 billion in 2030 at a compound annual growth rate (CAGR) of 3.8%. The growth in the forecast period can be attributed to increasing development of resistance-aware therapies, rising investments in novel antibiotics, expansion of rapid point-of-care diagnostics, growing focus on personalized infection treatment, increased adoption of telemedicine-based UTI management. Major trends in the forecast period include increasing adoption of broad-spectrum antibiotics, rising focus on rapid diagnostic testing, growing demand for targeted antimicrobial therapies, expansion of outpatient uti treatment options, enhanced emphasis on antimicrobial stewardship.

What Is The Driver Of The Urinary Tract Infection Treatment Market?

The rising prevalence of urinary tract infections is expected to propel the growth of the urinary tract infection treatment market going forward. Urinary tract infections refer to bacterial infections that affect the kidneys, bladder, ureters, and urethra, as well as other parts of the urinary system. Urinary tract infection treatment is essential, as it helps in several ways to address the infection and promote healing in urinary tract infections. For instance, in January 2023, according to the National Institute of Health, a US-based public health research agency, urinary tract infections were the seventh most common reason for a patient to be seen in an emergency department in the USA, constituting over one million visits annually. Of these, 22% (220,000) are considered complicated UTIs, and about 100,000 are admitted annually. Therefore, the rising prevalence of urinary tract infections is driving the growth of the urinary tract infection treatment industry.

Key Players In The Global Urinary Tract Infection Treatment Market

Major companies operating in the urinary tract infection treatment market are Pfizer Inc., Merck & Co Inc, Bayer AG, Sanofi S A, AstraZeneca plc, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Dr Reddy’s Laboratories Ltd, Cipla Ltd, Hikma Pharmaceuticals PLC, Lupin Limited, Torrent Pharmaceuticals Limited, Glenmark Pharmaceuticals Limited, Mylan N V, Aurobindo Pharma Ltd, Macleods Pharma Ltd, Zydus Cadila Healthcare Ltd, Abbott Laboratories, Shionogi & Co Ltd, Alkem Laboratories Ltd.

Global Urinary Tract Infection Treatment Market Trends and Insights

Major companies operating in the urinary tract infection treatment market are focusing on launching next-generation therapies, such as first-in-class oral antibiotics, to improve treatment outcomes and address rising antimicrobial resistance. First-in-class oral antibiotics refer to novel antibacterial agents with new mechanisms of action designed to treat uncomplicated UTIs caused by common and drug-resistant uropathogens, offering alternatives to older antibiotics facing reduced effectiveness. For instance, in March 2025, GlaxoSmithKline (GSK), a UK-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for the antibiotic drug Blujepa (chemical name gepotidacin) for the treatment of uncomplicated urinary tract infections in women and girls aged 12 years and older. Blujepa features a completely novel bacterial topoisomerase-inhibition mechanism, demonstrated efficacy against drug-resistant Escherichia coli, and a single-dose oral regimen, representing a major advancement in UTI treatment.

What Are Latest Mergers And Acquisitions In The Urinary Tract Infection Treatment Market?

In July 2025, Alembic Pharmaceuticals Inc., a US-based subsidiary of Indian multinational Alembic Pharmaceuticals Ltd., acquired Utility Therapeutics for $0.012 billion. Through this acquisition, Alembic aims to expand its US branded specialty pharmaceuticals portfolio by integrating Utility Therapeutics’ FDA-approved drug PIVYA (pivmecillinam) for the treatment of uncomplicated urinary tract infections. Utility Therapeutics Ltd is a UK-based biopharmaceutical company focused on UTI therapies.

What Defines the Urinary Tract Infection Treatment Market?

The urinary tract infection treatment market consists of sales of trimethoprim, sulfamethoxazole, cephalexin, and ceftriaxone. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Urinary Tract Infection Treatment Market Report 2026?

The urinary tract infection treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the urinary tract infection treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.